Study Links MOCCI to Lung Cancer Lymph Node Spread

Researchers at Fudan University Shanghai Cancer Center report that a metabolic protein helps lung cancer cells reach lymph nodes and suppress immune activity.

Updated on Nov. 13, 2026 in Cancer

Bold flat-color editorial illustration of pale cells linked by glowing amber filaments over a deep teal field, evoking a hidden biological pathway in lung cancer spread.
Researchers at Fudan University Shanghai Cancer Center found that a metabolic protein called MOCCI helps lung cancer cells spread to lymph nodes and suppress immune activity. AI Illustration. Upload story photo >

Researchers reported in Cancer Biology & Medicine that MOCCI-driven metabolic reprogramming drives lung cancer spread to lymph nodes. The study analyzed tissue from 10 patients and found MOCCI knockdown reduced cancer cell migration and invasion by more than 50%.

Why it matters

Lymph node metastasis is a key step in lung cancer progression, and the findings point to a specific metabolic pathway that may be relevant to future treatment research. The authors note that the results still require validation in larger patient cohorts.

The findings rest on profiling of 10 patients, 37 single-cell RNA sequencing samples and 27 spatial transcriptomics samples, with a more than 50% drop in cancer cell migration and invasion after MOCCI knockdown. The authors have not yet established outcomes in larger populations, and further validation is still needed.

The players

Fudan University Shanghai Cancer Center

A major oncology institution in Shanghai where the study was conducted.

Shanghai Institute of Materia Medica

A collaborating research institution contributing to the study.

The details

The researchers found that MOCCI-mediated OXPHOS reprogramming increases secretion of growth differentiation factor 15 (GDF15). GDF15 acts through TGFBR2 to promote exhaustion of follicular helper T cells and suppress neighboring B cells within metastatic lymph nodes.

Timeline

  1. Study results were reported on November 12, 2026, by the Chinese Academy of Sciences.

Health Landscape

The study applies single-cell RNA sequencing and spatial transcriptomics to map how metabolic reprogramming in lung cancer shapes immune suppression at metastatic sites. It builds on a growing body of tumor microenvironment research by linking a specific metabolic pathway to immune exhaustion in lymph nodes.

For patients, this research remains preclinical and does not change current lung cancer treatment or screening. Its relevance is mainly for researchers exploring metastasis-blocking approaches in future studies.

The takeaway

The study identifies a metabolic pathway that may help explain why lung cancer spreads to lymph nodes and how it weakens nearby immune responses. Clinical relevance depends on validation in larger patient groups and further mechanistic work.

Further reading

Explore more research on Cancer to see how metastasis studies fit into the wider field.

More information

Read the original Cancer Biology & Medicine study for full methods and data.

Source note: This article includes information reported by News-Medical.